BIO

Jill Olmstead, DNP, ANP-BC, is a gastroenterology nurse practitioner with Providence St. Jude Heritage Medical Group in Fullerton, California. She specializes in diagnosing and managing gastrointestinal disorders, offering compassionate, evidence-based care to improve patient outcomes.

MASLD-MASH Content Featuring Jill

MASLD Pharmacotherapy With Tessa Janovsky

September 2025

Join Tessa Janovsky, PA-C from Arizona Liver for a practical update on MASLD pharmacotherapy—from whole-patient metabolic management to liver-directed treatment. This session reviews why care must target the entire metabolic syndrome (weight, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risk), the impact of 7–10% weight loss (and why many patients need adjuncts), and how to choose between diet/physical activity, anti-obesity medications, and bariatric surgery for select cases. You’ll learn where GLP-1 receptor agonists fit (mechanism, expected weight and glycemic effects, GI side effects, peri-procedure anesthesia considerations, and use in compensated disease), when to use statins safely in fatty liver, and how to stage and monitor with FIB-4, FibroScan/elastography, and other non-invasive tests. Tessa also summarizes legacy data for vitamin E and pioglitazone (benefits and limitations) and highlights the first FDA-approved therapy for non-cirrhotic MASH with F2–F3 fibrosis, resmetirom—including mechanism (THR-β agonism), tolerability, drug–drug interaction checkpoints, and practical follow-up (restaging and lifestyle coaching). If you’re a GI/hepatology clinician or APP aiming to streamline risk reduction, staging, and evidence-based therapy for MASLD/MASH, this concise talk delivers clinic-ready guidance.

Watch Now arrow

MASLD Pharmacotherapy With Jill Olmstead

September 2025

Join Jill Olmstead, DNP from Providence Health for a practical, clinician-focused overview of MASLD pharmacotherapy and new treatment horizons for hepatic steatosis. This session in the GHAPP MASLD & MASH Community Network covers the shift in nomenclature, why care must be multidisciplinary (obesity, type 2 diabetes, dyslipidemia, hypertension, cardiovascular risk), and how to stage disease with FIB-4, noninvasive tests, and FibroScan before initiating therapy. Jill reviews lifestyle and weight-loss strategies, GLP-1 receptor agonists—their mechanisms, common GI side effects, and peri-procedure considerations due to delayed gastric emptying—plus where vitamin E and pioglitazone do and don’t fit today. She also walks through practical use of resmetirom for non-cirrhotic MASH with F2–F3 fibrosis (labs to order, monitoring, drug–drug interactions, and setting expectations alongside diet and exercise). If you’re a GI/hepatology clinician, APP, or primary-care partner looking to streamline risk reduction, staging, and evidence-based therapy for MASLD/MASH, this talk delivers step-by-step guidance you can use in clinic today.

Watch Now arrow

MASLD vs MetALD With Christina Hanson

September 2025

Discover the latest insights on MASLD and MetALD in this educational session from the GHAPP MASLD Community Network. Christina Hanson, FNP-C, walks through a real-world case study to highlight how common metabolic conditions like hypertension, hyperlipidemia, obesity, and PCOS intersect with alcohol use to drive liver disease progression. The session explores updated nomenclature replacing NAFLD/NASH, the role of FibroScan and elastography in staging fibrosis, and the importance of screening patients with metabolic risk factors for fatty liver. Learn how alcohol consumption contributes to liver injury, triglyceride elevation, and blood pressure changes, and how objective biomarkers such as PEth testing are transforming diagnosis beyond self-reporting. Christina also reviews lifestyle interventions, dietary strategies like the Mediterranean diet, and current treatment considerations for patients with advanced fibrosis (stage 3), including when to initiate HCC screening. Whether you are a hepatologist, GI specialist, or advanced practice provider, this session provides practical tools for evaluating and managing patients with MASLD, MetALD, and related liver health challenges.

Watch Now arrow

MASLD Pharmacotherapy With Christina Hanson

September 2025

Learn about the latest advances in MASLD and MASH pharmacotherapy in this educational session from the GHAPP MASLD Community Network. Christina Hanson, NP, reviews the evolving landscape of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), including the critical role of weight loss, cardiovascular risk reduction, and liver-directed therapies. The discussion covers current management strategies such as GLP-1 receptor agonists, bariatric interventions, statins, and lifestyle modification, while also exploring guideline-supported options like vitamin E and pioglitazone. Special attention is given to the first FDA-approved therapy for MASH, Resmetirom, including its mechanism, clinical trial results, safety considerations, and monitoring recommendations. Whether you are a hepatology specialist, primary care provider, endocrinologist, or advanced practice provider, this session highlights practical approaches to managing patients with MASLD and MASH and offers insights into emerging therapies that may shape future clinical practice.

Watch Now arrow

MASLD Basics With Jill Olmstead

August 2025

Join Jill Olmstead, NP, a seasoned gastroenterology nurse practitioner from Providence St. Joseph Health, for an in-depth overview of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Steatohepatitis) in this GHAPP MASLD Community Network presentation, proudly sponsored by Madrigal Pharmaceuticals. With over 20 years of clinical experience, Jill explains the evolving nomenclature from NAFLD/NASH to MASLD/MASH and how this impacts diagnostic criteria, patient communication, and multidisciplinary management. Learn how to identify steatotic liver disease, assess cardiometabolic risk factors, and use tools like FIB-4 and FibroScan to evaluate fibrosis and stratify risk. Jill walks through real-world case scenarios, highlighting when to order a liver biopsy, when to refer to hepatology, and how to apply AASLD guidelines in clinical practice. From evaluating elevated liver enzymes to addressing the global burden of MASLD and its progression to cirrhosis and HCC, this session is essential for providers navigating the complexities of modern liver disease management in both primary care and specialty settings.

Watch Now arrow

Management of Life Style Modification

January 2025

This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.

Watch Now arrow

Third Step of Life Style Management

January 2025

This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.

Watch Now arrow

Approved Medication for MASH/NASH

January 2025

This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.

Watch Now arrow

Types of Diet for the Treatment of MASLD

January 2025

This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.

Watch Now arrow

NITs to Identify High Risk MASH Patients

January 2025

Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.

Watch Now arrow
View All arrow arrow

Related Content

Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra

March 2025

This educational discussion dives into Rezdiffra, the first and only FDA-approved therapy for non-cirrhotic metabolic-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The talk provides a clinical deep dive into the progression of MASH and fibrosis, highlighting the risks of untreated disease and the importance of early intervention. A key focus is the thyroid hormone receptor beta mechanism, explaining how Rezdiffra directly targets liver-specific pathways to reduce hepatic fat accumulation and fibrosis. Additionally, the discussion covers the rigorous FDA approval process and dual efficacy endpoints, detailing how Rezdiffra achieved significant fibrosis improvement and steatohepatitis resolution in the MAESTRO-NASH trial. The session also provides practical insights into patient access, prescribing considerations, and managing common side effects. With over 2,000 patients studied, Rezdiffra has demonstrated a strong safety profile and offers a once-daily oral treatment option that represents a major advancement in MASH management. This discussion is essential for gastroenterologists, hepatologists, and endocrinologists managing patients with MASH, as well as primary care providers and cardiologists who play a role in identifying at-risk individuals. If you are a healthcare professional looking to stay updated on the latest MASH research and treatment strategies, this session provides the insights you need.

Watch Now arrow

Liver Model Overview

July 2025

Join Alison Moe, PA-C with United Digestive, as she walks through a hands-on demonstration using a life-sized liver model to help patients better understand fibrosis and liver disease progression. In this engaging and practical overview, Allison explains how different stages of liver fibrosis—from normal liver to cirrhosis and hepatocellular carcinoma—can be felt and visualized using a segmented anatomical model. She shares how this tool enhances patient education during discussions about non-invasive liver testing, such as FibroScan, CAP scores, FIB-4, ELF testing, and more. Designed to support visual learners and improve comprehension of disease state, this video is a valuable resource for clinicians and patients navigating the complexities of metabolic-associated fatty liver disease (MASLD) and its progression to MASH. Learn how tactile and visual teaching aids can bridge the gap between diagnostics and patient understanding in hepatology care.

Watch Now arrow

Differentiating Between F3 and F4

July 2025

In this comprehensive discussion, HoChong Gilles, a nurse practitioner with 25 years of hepatology experience at the Richmond VA Medical Center, explores the critical importance of accurately distinguishing between F3 (advanced fibrosis) and F4 (cirrhosis) in patients with MASH (metabolic-associated steatohepatitis). While both stages carry increased risks of liver-specific and overall mortality, Gilles explains that F3 may still be reversible with lifestyle changes or pharmacotherapy, whereas F4 signals irreversible liver damage with heightened risk of complications like portal hypertension, hepatic encephalopathy, and liver cancer. Viewers will gain a deeper understanding of how non-invasive tests—like FIB-4, ELF, FibroScan, and MRE—perform in identifying fibrosis stage, including their limitations and overlaps. Gilles also outlines when to consider liver biopsy, especially in cases with discordant test results, atypical features, or clinical uncertainty. This video emphasizes how staging accuracy informs eligibility for therapies, surveillance strategies like HCC screening, and overall prognosis. Learn how to approach this nuanced distinction in clinical practice and why F3 vs. F4 isn't just semantics—it's a turning point in patient care.

Watch Now arrow

Addressing Health Disparities: Equity Considerations in MASH/MASLD Care

July 2025

In this episode, Patrick Horne, NP at the University of Florida (UF Health), explores the impact of health disparities and socioeconomic inequality on the diagnosis and management of MASH (metabolic-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). With a focus on rural and underserved populations, Patrick discusses how limited access to quality healthcare, healthy food, exercise options, and non-invasive testing (NITs) like FibroScan or MRI elastography can delay diagnosis and worsen outcomes. He shares practical, empathetic strategies for individualizing care, such as using accessible tools like FIB-4 or APRI, promoting low-cost physical activity like walking or swimming, and providing culturally sensitive nutrition advice tailored to financial and geographic realities. Patrick emphasizes the provider’s role as a patient advocate and coach, helping patients navigate barriers and create sustainable lifestyle modifications. This episode offers key insights for clinicians working to close gaps in care and promote equity in liver disease management.

Watch Now arrow

Pharmacotherapy Review

July 2025

Join Christina Hanson, FNP-C, from South Denver Gastroenterology, as she provides an in-depth overview of the current pharmacologic treatment landscape for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). This expert-led session explores the three cornerstones of MASH management—lifestyle and weight loss interventions, cardiovascular risk reduction, and liver-directed therapy—while highlighting the evolving role of GLP-1 receptor agonists and the recent FDA approval of resmetirom, the first medication indicated for adults with MASH and moderate to advanced fibrosis. Christina also discusses clinical trial data from MAESTRO-NASH, reviews historical agents like vitamin E and pioglitazone, and offers practical guidance on patient selection, safety considerations, and monitoring strategies. Whether you’re a GI provider, hepatology specialist, or primary care clinician managing fatty liver disease, this video provides valuable insights into how emerging therapies are shaping the future of MASH treatment.

Watch Now arrow
View All arrow arrow

Latest News & Blogs

Wegovy® approved in the US for the treatment of MASH

At Aug 20, 2025

Check out the prescribing information here: https://bit.ly/novo-pi-wegovy

Read More arrow